T-cell activation via presentation of multiple tumor-associated antigens (null)

The phrase "T-cell activation via presentation of multiple tumor-associated antigens" describes a **biological process** rather than a specific molecular target. In this process, **tumor-associated antigens (TAAs)**—proteins that are overexpressed or aberrantly expressed in cancer cells—are processed into peptides and presented on the surface of these cells by major histocompatibility complex (MHC) molecules. **T-cells**, specifically CD8+ cytotoxic and CD4+ helper subsets, recognize these peptide-MHC complexes through their highly specific **T-cell receptors**. This interaction is central to the immune system’s ability to detect and destroy cancerous cells. Tumor-specific antigens are unique to cancer cells due to mutations or viral oncogenesis; TAAs may also be present at lower levels in normal tissues but are upregulated in tumors. The effectiveness and safety profile for immunotherapies targeting these processes depend heavily on the specificity and immunogenicity of the chosen antigen(s). Therapies such as CAR-T adoptive transfer or immune checkpoint blockade aim to enhance this natural immune surveillance mechanism but can be limited by issues like off-target effects if TAAs are not truly unique to tumors[1][2][3]. Because this entry refers broadly to an immunological mechanism rather than a discrete protein, gene, or receptor, it is not considered a canonical therapeutic target itself but rather describes how various targets might be engaged within immunotherapy strategies.

Other names

T cell activation by tumor antigensTumor antigen presentation to T cellsTumor-associated antigen-mediated T cell response

Enhancement of T-cell recognition and killing of tumor cells through increased presentation of tumor-associated antigens[1][2][3]